243 related articles for article (PubMed ID: 14679212)
1. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.
Cheng X; Kinosaki M; Takami M; Choi Y; Zhang H; Murali R
J Biol Chem; 2004 Feb; 279(9):8269-77. PubMed ID: 14679212
[TBL] [Abstract][Full Text] [Related]
2. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
Kostenuik PJ; Shalhoub V
Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
Hofbauer LC
Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
[No Abstract] [Full Text] [Related]
6. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
Hofbauer LC; Schoppet M
JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
[TBL] [Abstract][Full Text] [Related]
8. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.
Aoki K; Saito H; Itzstein C; Ishiguro M; Shibata T; Blanque R; Mian AH; Takahashi M; Suzuki Y; Yoshimatsu M; Yamaguchi A; Deprez P; Mollat P; Murali R; Ohya K; Horne WC; Baron R
J Clin Invest; 2006 Jun; 116(6):1525-34. PubMed ID: 16680194
[TBL] [Abstract][Full Text] [Related]
9. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?
Coetzee M; Kruger MC
South Med J; 2004 May; 97(5):506-11. PubMed ID: 15180028
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
[TBL] [Abstract][Full Text] [Related]
12. [Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent].
Andelković Z; Katić V; Mihajlović D; Zivković V; Petrović A; Lalosević D
Med Pregl; 2005; 58(7-8):362-7. PubMed ID: 16296579
[TBL] [Abstract][Full Text] [Related]
13. The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection.
Guillonneau C; Louvet C; Renaudin K; Heslan JM; Heslan M; Tesson L; Vignes C; Guillot C; Choi Y; Turka LA; Cuturi MC; Anegon I; Josien R
J Immunol; 2004 Feb; 172(3):1619-29. PubMed ID: 14734743
[TBL] [Abstract][Full Text] [Related]
14. The TNF receptor superfamily: role in immune inflammation and bone formation.
Cheng X; Kinosaki M; Murali R; Greene MI
Immunol Res; 2003; 27(2-3):287-94. PubMed ID: 12857975
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
Kostenuik PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
[TBL] [Abstract][Full Text] [Related]
16. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.
Schoppet M; Preissner KT; Hofbauer LC
Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):549-53. PubMed ID: 11950689
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
18. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
19. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand.
Schneeweis LA; Willard D; Milla ME
J Biol Chem; 2005 Dec; 280(50):41155-64. PubMed ID: 16215261
[TBL] [Abstract][Full Text] [Related]
20. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]